{"id":"W2735976365","doi":"10.1111/hiv.12532","title":"Week 96 results of the randomized, multicentre Maraviroc Switch (<scp>MARCH</scp>) study","year":2017,"lang":"en","type":"article","venue":"HIV Medicine","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Hip and Knee Clinic; AIDS Vancouver","funders":"Medical Research Council; Pfizer; Australian Government; Gilead Sciences; Department of Health and Aged Care, Australian Government; Meso Scale Diagnostics; AbbVie; GlaxoSmithKline; Merck; Thailand Research Fund; ViiV Healthcare; Bristol-Myers Squibb; University of New South Wales; Abbott Fund","keywords":"Maraviroc; Medicine; Regimen; Randomization; Randomized controlled trial; Internal medicine; Clinical endpoint; Confidence interval; Viral load; Ritonavir; CCR5 receptor antagonist; Population; Intention-to-treat analysis; Gastroenterology; Human immunodeficiency virus (HIV); Immunology; Antiretroviral therapy; Chemokine; Receptor; Chemokine receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005020171,0.001765797,0.002542111,0.0003939147,0.0003897519,0.001566228,0.0007801254,0.001839783,0.009039361],"category_scores_gemma":[0.004487558,0.0005794559,0.002749239,0.0003182516,0.000600971,0.0009648473,0.0004395548,0.002913787,0.001805101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005581476,"about_ca_system_score_gemma":0.0006330702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000327792,"about_ca_topic_score_gemma":0.0004967348,"domain_scores_codex":[0.9980944,0.001064679,0.0001420783,0.0003114587,0.0002169978,0.0001703969],"domain_scores_gemma":[0.9971358,0.0007481088,0.0009870146,0.0003663932,0.0002215846,0.0005412098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.976536,0.00274322,0.001651113,0.0003363647,0.001528316,0.0000357995,0.00002683377,0.0003755996,0.00252494,0.00004434714,0.0014724,0.01272508],"study_design_scores_gemma":[0.892538,0.08068952,0.01949887,0.00008871338,0.001890032,0.0001046083,0.00001887798,0.0004602348,0.001885772,0.0002257086,0.002559422,0.00004025017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781908,0.005750637,0.0009280149,0.0007128997,0.0004279265,0.002264266,0.006771804,0.0002223876,0.004731231],"genre_scores_gemma":[0.986163,0.001343921,0.001174064,0.0009624074,0.0003144518,0.001847668,0.003658791,0.00007778546,0.00445786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009039361,"threshold_uncertainty_score":0.0302397,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02427085731975139,"score_gpt":0.2941855971316036,"score_spread":0.2699147398118522,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}